ClaritevCTEV +1.27%54 10-Year ROIIC % is -0.09 as of Dec. 2025. GuruFocus rates CTEV with a GF Score™ of 54/100 and a GF Value™ of $31.34 (Fairly Valued). The stock has 6 warning signs investors should review. Among 489 Healthcare Providers & Services companies, Claritev ranks worse than 61.15% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Claritev does not have enough data to calculate 10-Year ROIIC %.
Claritev (NYSE:CTEV) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Claritev 10-Year ROIIC % Related Terms
Claritev 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Claritev's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTEV vs MDRX, EVH, PHR: 10-Year ROIIC % Comparison
For the Health Information Services subindustry, Claritev's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Claritev 10-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Claritev's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Claritev's 10-Year ROIIC % falls into.
Claritev's 10-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( 34.334196 (Dec. 2025) - (Dec. 2015) )
/
( 4734.776 (Dec. 2025) - (Dec. 2015) )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Claritev (CTEV) has a 10-Year ROIIC % of -0.09 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Claritev and its competitors. According to the industry distribution chart, Claritev ranks #299 out of 489 companies in the Healthcare Providers & Services industry, placing it in the top 61.1%.
Is Claritev's 10-Year ROIIC % too high?
Claritev's current 10-Year ROIIC % is -0.09. Based on the distribution chart, Claritev ranks #299 out of 489 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Claritev has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Claritev's 10-Year ROIIC % compare to MDRX and EVH?
According to the Healthcare Providers & Services industry distribution chart, Claritev ranks #299 out of 489 companies for 10-Year ROIIC %. This places Claritev in the lower half of its industry. The industry median 10-Year ROIIC % is 3.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Healthcare Providers & Services company?
The median 10-Year ROIIC % among Healthcare Providers & Services companies is 3.49, based on 489 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Claritev and its competitors. For the Healthcare Providers & Services industry, the median 10-Year ROIIC % is 3.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Claritev's current 10-Year ROIIC % is -0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Claritev stock overvalued right now?
Based on GuruFocus' analysis, Claritev (CTEV) is currently considered Fairly Valued. The stock's GF Value™ is $31.34, compared to a current price of $32.02 — trading 2.2% above its estimated fair value. The current 10-Year ROIIC % is -0.09. Claritev's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Claritev (CTEV), the current 10-Year ROIIC % is -0.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Claritev (CTEV) Overvalued in 2026?
Based on GuruFocus' analysis, Claritev stock appears to be overvalued.
The current stock price of $32.02 is trading 2.2% above its estimated GF Value™ of $31.34.
GuruFocus considers Claritev to be Fairly Valued.
Key valuation signals for CTEV:
10-Year ROIIC %: -0.09
GF Value™: $31.34 vs. price of $32.02 (2.2% above fair value)
No single metric tells the full story. See the CTEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The company's focus is on being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
54GF Score
Get the complete analysis for CTEV
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTEV has been successfully added to your 
